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Biocatalytic Synthesis of Stereospecific Triketide 
Lactones using Polyketide Synthases 
 
Bradley Alexander  
 
Institute for Cellular and Molecular Biology, The University of Texas at Austin 
 
 
 
Polyketide synthases are modular enzymes that create and modify large acyl chains. 
The domains and modules of polyketide synthases allow us to create molecules that 
resemble naturally occurring products by applying a biocatalytic in vitro in vivo 
approach to a diketide acyl chain. We showed that a triketide lactone of desired 
stereochemistry could be made using a domain and module from the polyketide 
synthase found in Saccharopolyspora erythraea, 6-Deoxyerythronolide B Synthase. 
Future projects will explore this approach using different domains and modules.  
 
Background: 
 
Chirality and Molecular Libraries 
 
Molecules that contain a stereocenter, an atom that has at least three different atoms 
attached, can be chiral or achiral. Chirality is the asymmetric geometric property of 
molecules. This means that a chiral molecule cannot be superimposed on its mirror image 
(Figure 1).  Therefore, molecules can have the same molecular formula and connectivity, 
yet differ in three-dimensional orientation. These molecules are called stereoisomers and 
despite having structural similarities, their chemical properties can differ greatly. This is 
why understanding the chirality of molecules is crucial in the field of biochemistry and 
organic chemistry1. Controlling chirality during chemical synthesis is often a difficult 
process. Even when stereocenters can be controlled most synthetic techniques lead to low 
product yield. If chirality can be controlled with reasonable product yield it is possible to 
generate large molecular libraries. 	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Figure 1: Molecule (a) contains a chiral center and cannot be superimposed on its mirror 
image.	  
 
Numerous fields require new molecules for continued growth, but standard synthetic 
approaches are falling short of this high demand2. In the medical field chemical synthesis 
can be an expensive process and has major application issues. The first of these issues is 
that chemically-synthesized molecules typically have low hit rates in high throughput 
screening3. Second, these molecules tend to fail in the clinical stages of testing when 
patients become involved. Both of these problems stem from the fact that these molecules 
lack the characteristics of similar natural products. In addition to chemically-synthesized 
molecules we can also discover new natural products. This is how a majority of 
antibiotics used in the medical field are generated4. Unfortunately, this process can be 
timely and it seems like the number of useful products undiscovered has decreased 
significantly. An alternative approach to this growing problem is using polyketide 
synthases in a biocatalytic process that allows for libraries of new molecules to be made 
that have natural characteristics5. This strategy would nullify many of the problems that 
come with the traditional approaches to discovering new molecules.  
 
Polyketide Synthases 	  
Polyketide synthases (PKSs) are capable of producing stereochemically rich natural 
products called polyketides. Type 1 PKSs are large and highly modular. They are 
responsible for producing more complex polyketides. Polyketides are secondary 
metabolites produced by organisms to gain a competitive advantage6. They also serve a 
commercial use as antibiotics, antifungals, and immunosuppressants7. The enzyme 
domains and modules responsible for making these polyketides can be used in a 
biocatalytic process capable of producing new polyketides and other stereochemically 
rich compounds. These new polyketides or polyketide-like molecules could hold valuable 
chemical properties like their natural analogues. 
 
Polyketide synthases can be thought of as molecular assembly lines (Figure 2) capable of 
catalyzing the condensation of acyl-CoA building blocks. The enzyme is broken up into 
domains that each help in the processing and modification of the polyketide products. A 
module consists of multiple domains functioning as one unit. A minimal module is 
composed of three domains: an acyltransferase (AT) that selects the initial priming unit 
and extender units that are added to the acyl chain. Typically the AT is the limiting 
domain in most biocatalytic approaches involving polyketide synthases. A ketosynthase 
(KS) that accepts the polyketide chain from upstream modules and catalyzes the 
condensation of extender units held by the acyl carrier protein (ACP); and the ACP is 
capable of moving the growing acyl chain between enzyme domains through the use of 
an ~18 Å phosphopantetheinyl arm. 
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The other enzyme domains in polyketide synthases are responsible for β-carbon-
processing8. Ketoreductases (KRs) are responsible for the reduction of β-keto groups to 
β-hydroxyl groups. Dehydratases (DHs) remove the β-hydroxyl group through a 
dehydration reaction. The resulting product is an alkene and enoylreductases (ERs) 
further reduce the β-carbon to and alkane after a dehydration reaction. Both the 
ketoreductase and enoylreductases use the coenzyme NADPH to reduce the growing 
polyketide. These domains are not necessary in polyketide synthesis, as they have no 
effect on the elongation of the acyl chain. These β-carbon processing domains are not 
always present in polyketide synthases.  	  	  	  
	  	  
Figure 2: The growing acyl chain is passed around to each domain with help from the 
phosphopantetheinyl arm attached to ACP. 
 
Ketoreductases are classified into three main types that can further be broken down into 
subtypes. A-type KRs generate L-β-hydroxyl groups, B-type KRs generate D-β-hydroxyl 
groups, and C-type KRs are reductase-incompetent. KRs that reduce α- unsubstituted 
intermediates are labeled A0 or B0-type. KRs that reduce α-substituted intermediates are 
further divided into those producing D-α-substituents which are denoted with a “1” and 
those producing L-α-substituents which are denoted with a “2”9. 	  
Application	  of	  6-Deoxyerythronolide B Synthase in Biocatalytic Chemistry	  
 
Our research focused on using the domains and modules from the type I PKS 6-
Deoxyerythronolide B Synthase (DEBS) to create a triketide lactone of desired 
stereochemistry. This polyketide synthase is found in Saccharopolyspora erythraea 
(Figure 3) and is responsible for assembling the 6-deoxyerythronolide B (6-DEB) 
scaffold of erythromycin. DEBS consist of three large proteins, DEBS 1, 2 and 3, that 
each exists as dimers of two modules. These proteins work together to assemble seven 
precursors consisting of one propionyl-CoA starter unit and six (2S)-methylmalonyl 
Coenzyme A (CoA) extender units into 6-DEB. Each set of modules controls the 
incorporation of each extender unit into the growing polyketide. The modules that 
incorporate extender units typically consist of the three domains that make up a minimal 
module and up to three optional β-carbon-processing domains. DEBS is one of the most 
studied polyketide synthases and has been proven a useful tool in creating more 
AT	   DH	  	  ER	  KR	     ACP 
AT	   DH	  	  ER	  KR	     ACP KS 
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polyketide-like molecules. My research has taken the highlighted module, EryMod6TE, 
and the underlined domain, EryKR1, from DEBS and applied it to precursor-directed 
biosynthesis. This system was chosen because it is one of the most well studied PKS’s 
and a wealth of data10,11 is available on the system’s properties.  
 
 
 
 
 
Figure 3: This is a simplified representation of the modules that form DEBS. The final 
module is the module of interest for this synthetic approach.  
 
 
Synthesis of Triketide Lactones: 
 
Triketide lactones (TKLs) are cyclical molecules that we have created using precursor 
directed synthesis involving the domains and modules from DEBS. These molecules 
contain four stereocenters, allowing for a maximum of 16 stereoisomers to be created. 
The number of stereoisomers is 2n, where n is the number of stereocenters. The remainder 
of this paper will focus on the details of triketide lactone synthesis and discuses the future 
projects that could benefit from this biocatalytic process. 
 
Overview of the In Vitro In Vivo Synthesis of a Triketide Lactone  
 
Creation of a triketide lactone of desired stereochemistry begins with the synthesis of the 
diketide acyl chain α-methyl, β-ketopentanoyl-S-N-acetylcysteamine (PPSNAc). This 
process begins with the synthesis of (E)-4-ethylidene-3-methyloxetan-2-one (diketene) 
and S-N-acetylcysteamine (SNAc). Due to the simplicity of these molecules, they all lack 
stereocenters, we were able to produce them on a gram scale. The final precursor, 
PPSNAc, is then fed into a ketoreductase domain in vitro that is capable of reducing the 
β-keto group. The reduced product is then incubated in an E. coli strain, K207, that 
carries the genes necessary for protein expression of an enzyme module capable of 
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catalyzing a Claisen condensation reaction between PPSNAc and an extender unit. The E. 
coli strain is also capable of generating the extender unit, methylmalonyl-CoA. The 
product of this reaction is a triketide lactone (Figure 4).  
 
 
 
 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: This is a visual representation of in vitro in vivo biocatalytic process that 
creates triketide lactones. The underlined triketide lactone is the desired product from this 
synthetic process. 
 
Precursor Synthesis 
 
This section reviews the reactions needed to create the precursor molecules: (E)-4-
ethylidene-3-methyloxetan-2-one, S-N-acetylcysteamine, and α-methyl, β-ketopentanoyl-
S-N-acetylcysteamine. 
 
(E)-4-ethylidene-3-methyloxetan-2-one (Diketene) Synthesis: 
 
Diketene synthesis begins with propionyl chloride. Triethylamine acts as a base that is 
capable of removing the acidic hydrogen adjacent to the keto group. The removal of the 
hydrogen leads to the formation of a radical intermediate as the chloride atom acts as a 
leaving group. The radical intermediate then reacts with itself to form a 4-member 
diketene ring (Figure 5).  
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Figure 5: Propionyl chloride, molecule on the left, has the acidic hydrogen underlined. 
The molecule on the right, diketene, is the resulting product of the reaction. 
 
S-N-acetylcysteamine (SNAc) Synthesis: 
 
The formation of S-N-acetylcysteamine begins with 2-aminoethanethiol and acetic 
anhydride. 2-aminoethanethiol become nucleophilic after its thiol group is deprotonated 
by KOH. The newly formed nucleophile then attacks a keto group on acetic anhydride 
and carboxylic acid acts as a leaving group. The newly formed molecule is S-N-
acetylcysteamine (Figure 6).  
 
 
 
Figure 6: Structure of S-N-acetylcysteamine. 
 
α-methyl, β-ketopentanoyl-S-N-acetylcysteamine (PPSNAc) Synthesis: 
 
The cyclized diketene molecule and SNAc are used in the synthesis of PPSNAc. The 
thiol group on SNAc is deprotonated using triethylamine. The deprotonated SNAc then 
acts as a nucleophile that opens the 4-member diketene ring by attacking the ketone 
functional group. The result of this ring opening reaction is PPSNAc (Figure 7). 
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Figure 7: Structure of α-methyl, β-ketopentanoyl-S-N-acetylcysteamine. 
 
 
In	  Vitro	  Reduction	  of	  PPSNAc	  using	  EryKR1	  	  
After the diketide acyl chain PPSNAc has been synthesized, it is reduced in vitro using a 
ketoreductase (KR). EryKR1 is the KR domain from the first module in DEBS. It is a B2-
type KR that generates L-α-alkyl-D-β-hydroxyl products. This can be seen when the 
diketide PPSNAc is incubated with the KR in vitro. The product of the reaction is L-α-
methyl, D-β-hydroxyl-S-N-acetylcysteamine. It should be noted that these reduction 
reactions are fueled by the coenzyme NADPH. As EryKR1 reduces the β-keto group on 
PPSNAc, NADPH is oxidized. The oxidation of D-glucose to D-gluconolactone using 
glucose dehydrogenase (GDH) is coupled to the reaction for NADPH regeneration 
(Figure 8)12. 	  
	  	  
Figure 8: Ketoreductase, from module 1 of DEBS, is coupled with glucose 
dehydrogenase for continued NADPH regeneration.  
 
 
In Vivo Condensation of L-α-methyl, D-β-hydroxyl-S-N-acetylcysteamine  	  
After PPSNAc has been reduced to L-α-methyl, D-β-hydroxyl-S-N-acetylcysteamine it is 
then incubated with the E. coli strain K207. This strain contains genes that express the 
EryMod6TE module of DEBS 3 (Figure 9). This strain of E. coli is also capable of 
producing methylmalonyl-CoA if propionate is introduced into the culture. When an 
extender unit, methylmalonyl-CoA, is introduced to this system the AT domain 
presumably accepts and charges the ACP domain. The KS domain then catalyzes the 
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Claisen condensation reaction between L-α-methyl, D-β-hydroxyl-S-N-acetylcysteamine 
and the extender unit, methylmalonyl-CoA, which is attached to the ACP domain. After 
this condensation process occurs the EryKR6 domain, an A1-type KR, reduces the β-keto 
group on the elongated acyl chain. The newly formed hydroxy group then acts as a 
nucleophile attacking the remaining keto group. The sulfur atom attached to the 
phosphopantetheinyl arm on ACP acts as a leaving group as the molecule undergoes self-
cyclization. The end result is the desired triketide lactone with 4 different stereocenter. 
(Figure 10). 	  	  	  	  	  	  	  	  	  
Figure 9: EryMod6TE consist of the three domains that make up a minimal module and 
an A1-type KR. The thioester at the end of the module is responsible for a hydrolase 
reaction that frees the acyl chain from DEBS. 	  	  	  	  	  
 
 
 
 
 
 
 
 
 
 
Figure 10: The final product from this in vitro in vivo biocatalytic approach.  	  	  
 
 
 
 
 
 
 
 
KS	   AT	   KR	   ACP	   TE	  
SH	   SH	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Materials and Methods: 
 
(E)-4-ethylidene-3-methyloxetan-2-one (Diketene) 
 
Dichloromethane (150 mL) and triethylamine (18.72 mL) were added over 3Å molecular 
sieves to a flamed-dried flask and cooled to 0°C. Propionyl chloride (19.02 mL) was 
added dropwise at 0°C over a period of 90 minutes. The propionyl chloride should be 
added more slowly if the reaction begins to take a red color. The reaction is then stirred at 
room temperature overnight, concentrated under vacuum, and filtered with brine to 
remove the triethylammonium chloride salt. The crude product is purified via dry flash 
column chromatography (Silica and 100% Ethyl acetate). Due to trace amounts of water 
vapor becoming significant, this reaction is not scalable.  
 
S-N-acetylcysteamine (SNAc) 
 
dH2O (50ml), NaHCO2 (6.75g), and KOH (1.5g) were added to a 250 ml flask. 2-
aminoethanethiol (3.05 g) was then added to the flask and allowed to stir for 10 minutes. 
Acetic anhydride (2.28 mL) was then added to the flask and the reaction was stirred over 
night. The reaction is then quenched with HCl and extracted using EtOAc before being 
concentrated under vacuum. This reaction is scalable.  
 
α-methyl, β-ketopentanoyl-S-N-acetylcysteamine (PPSNAc) 
 
To a flame dried flask, methyl diketene dimer (427 mg) and N-acetylcysteamine were 
added to dichloromethane (30 mL) at 0°C. Catalytic triethylamine was added, and the 
reaction warmed to room temperature and stirred overnight. After the reaction goes to 
completion it is dried over sodium sulfate and washed in saturated NaCl. The crude 
product is afforded after being concentrated over vacuum. The crude product is purified 
via dry flash column chromatography (Silica and 50% Ethyl acetate:Hexane). 
 
Reduction of α-methyl, β-ketopentanoyl-S-N-acetylcysteamine using EryKR1 
 
The following substrates were added to a flask and were allowed to stir overnight: 
 
 6 mL H20 
 3 mL PO3 
 4 mL Glycerol 
 1.3 mL Glucose 
 0.4 mL NaCl 
 Catalytic amount of NADP+ 
 5 mL EryKR1 
 
The reduced product, L-α-methyl, D-β-hydroxyl S-N-acetylcysteamine, is then extracted 
using EtOAc and concentrated under vacuum.  
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In vivo synthesis of triketide lactone using EryMod6TE 
 
Starter cultures of E. coli K207 (50 ml) were grown overnight and used to inoculate 1L of 
prewarmed (37°C) TSB, supplemented with 50 mg/L kanamycin. When OD600 = 0.4, the 
media was cooled (15°C) and protein expression was induced with 0.5 mM IPTG. After 
protein expression is induced L-α-methyl, D-β-hydroxyl S-N-acetylcysteamine is added 
and incubated with the protein for 16 hours. The culture was then centrifuged and cellular 
debris was removed. The triketide product is then extracted using EtOAc and 
concentrated under vacuum. The crude product is purified via dry flash column 
chromatography (Silica and 75% Ethyl acetate:Hexane). 
 
 
Results 
 
During synthesis of the precursor molecules a high percent yield was regularly seen. The 
yields for each precursor ranged from 30-50% and the structure for each molecule was 
analyzed using mass spectroscopy and NMR. Through an in vitro in vivo biocatalytic 
process, it was possible to synthesize the expected triketide lactone. After the purification 
of the targeted triketide lactone using column chromatography the molecule was 
examined using mass spectroscopy (Figure 11). This synthetic process was performed 
twice and both times yielded the same result. However, the final yield of the triketide 
lactone was lower than expected (>5%). The reduction step with EryKR1 exhibited a 
yield of approximately 30%, but during the final incubation step with E. coli much of the 
product was lost. This could have stemmed from poor expression of the EryMod6TE 
module or inducing the protein at a non-ideal optical density.  
 
 
 
 
 
Obs. m/z Calc. m/z Charge Abund Formula Ion/Isotope Target 
Mass 
Error 
(ppm) 
195.09920 195.09920 1 2458.92 C9H16O3 (M+Na)+ -2.39 
196.10260 196.10260 1 280.73 C9H16O3 (M+Na)+ -1.58 
197.09880 197.10450 1 82.1 C9H16O3 (M+Na)+ 28.88 
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Figure 11: The large peak at 195.09920 confirms the presence of the targeted triketide 
lactone.  
 
Limitations and Future Plans 
 
The success of this biocatalytic approach shows the value of using polyketide synthases 
in synthesizing compounds with multiple stereocenters. There are still 15 triketide lactone 
stereoisomers that can be created from this in vivo in vitro approach. However, there are 
some limitations. Not all KR domains are conducive to reducing foreign molecules. More 
specifically, type A KRs have been shown to have higher specificity than type B KRs. 
Also there are limitations in what polyketide synthases are capable of processing. The AT 
domain acts as highly selective gatekeepers that will only charge the ACP domain with a 
limited number of extender units. This does limit the complexity of acyl chains that can 
be created. Despite the drawbacks to this synthetic approach, this technique still holds 
value as a new pathway to more molecules.  I am currently applying this technique to 
propyl-acetyl SNAc and butyl-acetyl SNAc. These molecules will be reduced using 
TylKR1, a B type KR, and then fed through EryMod6TE. The goal of this current project 
is to demonstrate that triketide lactones can be generated using a different KR in vitro.  
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